(Q34074708)

30 July 2017

1 reference

title

Oncolytic viruses as novel anticancer agents: turning one scourge against another (English)

1 reference

30 July 2017

1 reference

Smith ER

1

1 reference

30 July 2017

Chiocca EA

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

311-327

1 reference

Infection by Herpes Simplex Virus and Cells of Nervous System Origin: Characterization of a Non-permissive Interaction

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

An experimental model of retrovirus gene therapy for malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Viruses, host responses, and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Mechanism of regression of tumours induced by polyoma virus in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A new approach in specific, active immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Recruitment of the retinoblastoma protein to c-Jun enhances transcription activity mediated through the AP-1 binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Genetic recombination in human melanoma and astrocytoma cell lines involves oncogenes and growth factor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Complementary adenoviral vectors for oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

The effect of ganciclovir on herpes simplex virus-mediated oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.311

21 January 2018

Identifiers

DOI

10.1517/13543784.9.2.311

1 reference

30 July 2017

1 reference